deguelin has been researched along with Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Billi, AM; Bortul, R; Cappellini, A; Conte, R; Grafone, T; Mantovani, I; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL | 1 |
| Chen, Y; Cui, G; Li, R; Shu, W; Wu, Q | 1 |
2 other study(ies) available for deguelin and Leukemia
| Article | Year |
|---|---|
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Erythropoietin; Etoposide; HL-60 Cells; Humans; Leukemia; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rotenone; Signal Transduction; Stem Cell Factor; Stem Cells | 2005 |
Deguelin represses both the expression of nucleophosmin and some nucleoporins: Nup88 and Nup214 in Jurkat cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Humans; Jurkat Cells; Leukemia; Nuclear Pore Complex Proteins; Rotenone | 2008 |